Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Acadia Pharmaceuticals Q3 Revenue Grows to $342.29 Million Amid Portfolio Expansion

Acadia Pharmaceuticals delivered significant year-over-year revenue growth in the third quarter of 2026, reaching $342.29 million. While operational efficiency led to a rise in pretax income to $80.44 million, the company saw a 25.4% decrease in net income compared to the previous year.

Approximately, health, medical treatment, medicine. Stock photo illustrating Acadia Pharmaceuticals' financial results story.
ACADIA PHARMACEUTICALS INC · Photo: HeungSoon / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 342.29278.63
Pretax Income 80.4444.60
Net Income 53.5271.78
Diluted EPS 0.310.42
Net Income YoY
-25.4%

Key highlights

  • Total revenue climbed to $342.29 million, a 22.8% increase from $278.63 million in Q3 2025
  • Pretax income expanded to $80.44 million, up from $44.60 million in the prior year period
  • Net income for the quarter was $53.52 million, reflecting a year-over-year decline of 25.4%
  • Diluted earnings per share decreased to $0.31 from $0.42 in the same quarter last year
  • Management provided full-year 2026 revenue guidance between $1,265 million and $1,295 million

How the Period Went

Acadia Pharmaceuticals reported total revenue of $342.29 million for the third quarter of 2026, representing a 22.8% increase over the $278.63 million recorded in the same period last year. This growth was accompanied by a substantial rise in pretax income, which reached $80.44 million compared to $44.60 million in the prior year. However, net income for the quarter declined by 25.4% to $53.52 million, down from $71.78 million in Q3 2025. This resulted in a diluted earnings per share of $0.31, a decrease from the $0.42 reported twelve months prior, as the company balanced revenue expansion with shifting bottom-line dynamics.

Margins and Profitability

The company demonstrated improved operational leverage as pretax income nearly doubled year-over-year. This performance suggests a significant expansion in pretax margins, driven by higher sales volumes of commercial products and disciplined management of operating expenses. Despite the growth at the pretax level, the final net income figure was $53.52 million, affected by tax or non-operating items that caused it to diverge from the pretax trend. Acadia continues to transition toward sustained profitability, utilizing the cash flow generated by its established Parkinson's disease psychosis and Rett syndrome franchises to fund ongoing late-stage clinical development.

Business Overview

  • Specializes in small-molecule drug development for central nervous system disorders
  • Commercial portfolio led by NUPLAZID for Parkinson’s disease psychosis
  • Commercial portfolio includes DAYBUE, the first treatment approved for Rett syndrome
  • Pipeline focuses on unmet needs in neurology and psychiatry segments
  • Upcoming milestones include Phase 2 RADIANT study data for remlifanserin in late 2026

Financial Context

With a market capitalization of approximately $3.71 billion, Acadia is currently trading at a price-to-earnings ratio of 9.63x. This valuation follows a period of sequential revenue growth throughout 2026, with the Q3 result of $342.29 million exceeding the $308.0 million and $268.0 million reported in the second and first quarters, respectively. While the stock has experienced a 16.17% decline over the past quarter, it has shown recent upward momentum with a 6.76% gain over the last month. The company's updated full-year revenue guidance suggests a stable outlook for its primary commercial products through the end of the fiscal year.

ACADIA PHARMACEUTICALS INC share price · last month
Line chart of ACADIA PHARMACEUTICALS INC's share price over the last month, from $19.80 on 19 Oct → $18.67 on 16 Nov; our story on 5 Nov at $21.47.

Down 13.0% since our story on 5 Nov: $21.47 when we broke it → $18.67 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$19.80
20 Oct$20.44
21 Oct$20.19
22 Oct$20.31
23 Oct$19.73
26 Oct$19.74
27 Oct$20.17
28 Oct$20.32
29 Oct$20.76
30 Oct$20.59
2 Nov$20.47
3 Nov$20.57
4 Nov$21.47
5 Nov$21.24
6 Nov$21.23
9 Nov$16.50
10 Nov$18.28
11 Nov$18.37
12 Nov$18.14
13 Nov$18.75
16 Nov$18.67

Industry Landscape

The biotechnology sector remains focused on specialized orphan drugs, where Acadia maintains a strong footprint. Industry conditions are characterized by steady demand for CNS therapies, though competition for market share in specialized neurology remains high. Acadia's P/E ratio of 9.63x is relatively low compared to many biotech peers, reflecting a market positioning that balances commercial execution with clinical development risk. As the sector faces rigorous regulatory standards, Acadia’s ability to generate significant commercial revenue from two distinct products provides a diversified base relative to single-product development-stage companies.

Recent quarters and guidance
DateAnnouncementAmount
04 Nov 2026Q3 2026 total revenuesSource: businesswire.com$342.0 Million
04 Aug 2026Q2 2026 total revenuesSource: morningstar.com$308.0 Million
06 May 2026Q1 2026 total revenuesSource: acadia.com$268.0 Million
25 Feb 2026Q4 2025 total revenuesSource: ir.acadia.com$284.0 Million
05 Nov 2025Q3 2025 total revenuesSource: businesswire.com$278.6 Million
06 Aug 2025Q2 2025 total revenuesSource: businesswire.com$264.6 Million
ACADIA PHARMACEUTICALS INC · financial snapshot
Share price$21.47
Market cap$3.7B
Revenue (annual)$1.1B
P/E (TTM)9.6×
1-month price change+6.76%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Acadia Pharmaceuticals Inc. announcing third quarter 2026 financial results.

Read the filing ↗

Track ACADIA PHARMACEUTICALS INC live

Get the next ACADIA PHARMACEUTICALS INC SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.